Symbols

SANA

Sana Biotechnology·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SANA

Sana Biotechnology, Inc.

A company focused on creating and delivering engineered cells as medicines

Industry

Biological Technology

Established Date

07/13/2018

Listing Date

02/04/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

142

Fiscal Year Ends

12-31

Website

www.sana.com

Security Type

Common stock

Office address

188 East Blaine Street, Suite 350, Seattle, Washington 98102

Business

Introduction

Sana Biotechnology, Inc., was incorporated in Delaware on July 13, 2018. The company is a biotechnology company that develops drugs using engineered cells. Its business includes identifying and developing potential product candidates, conducting preclinical research, and building production capabilities. Sana Biotechnology is also committed to the preparation and execution of clinical trials of its product candidates and provides support for clinical trials of product candidates developed using its technology. In addition, the company focuses on new technology acquisition, staffing, business planning, maintaining its intellectual property portfolio, raising capital and providing general administrative support for the above-mentioned tasks.

Company Financials

EPS

SANA has released its 2025 Q4 earnings. EPS was reported at -0.21, versus the expected -0.14, missing expectations. The chart below visualizes how SANA has performed over recent quarters, highlighting trends in earnings surprises.